Navigation Links
Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
Date:4/10/2013

tric, esophageal and ovarian cancers. 

Study Results

Results of the preclinical study showed that the combination of MM-111 with trastuzumab is synergistic in a preclinical HER2-expressing gastric cancer model. Additionally, the study found that heregulin desensitizes gastric tumor cells to the effects of trastuzumab and paclitaxel.  The addition of MM-111 to the paclitaxel and trastuzumab regimen, or the addition of MM-111 to either paclitaxel or trastuzumab, restored sensitivity of tumors to treatment in the model.

About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

Forward-Looking Statement
To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack's strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. In this press release, Merrimack's forward-looking statements include statements about the potential effectiveness of its drug candidates and its ability to translate preclinic
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
2. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
3. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
4. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
5. Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM
6. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
7. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
8. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
9. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
11. Valeant Pharmaceuticals Provides Update to Recent Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Pranoprofen ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma ... as an inflammatory drug, pranoprofen was later developed ... under the trade name of pranopulin for the ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 2010 Genomic Health, Inc. (Nasdaq: GHDX ) today ... 30, 2010. Total revenue increased to $46.3 million in ... third quarter of 2009.  Product revenue was $45.8 million in the ... $38.9 million in the third quarter of 2009. ...
... Nov. 8, 2010 PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly dividend of $.12 per share ...  The dividend will be payable December 15, 2010, to shareholders ... public in 1984 Mesa Labs has maintained strong cash positions ...
Cached Medicine Technology:Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 8
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... serve as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who ... help the college expand its reach and impact through innovative technologies and strategies. , ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... one of two inventors from Miller Place, N.Y. "I specialize in manual therapy, ... discomfort. In addition, it can be used for additional muscle dysfunction throughout the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections ... have shown through research to improve treatment outcomes. This localized treatment seems ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number ... recently transitioned management companies to partner with Wound Care Advantage (WCA) to utilize ... center. , Transitioning wound care management providers can be a complex undertaking. ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... Texas Mutual Insurance Company, an,aggressive tort reform advocate ... pending litigation in which the insurance company tried,to overturn ... for a workplace injury,a Dallas state district judge ruled ... falsified medical record,Texas Mutual had no evidence to continue ...
... CHICAGO, Jan. 9 To make your New ... Pretzels(R) (K&SGP) introduces its,Empowered Pretzel(TM), the first of ... healthful twist on the traditional pretzel. The,pretzel is ... http://www.kimandscotts.com or by calling the company at ...
... Health Care,Associates, Inc. (MHA), the nation,s largest alternate ... members, Mr. Barry R. Freedman and,Mr. Brian Wheelan ... and Mr.,Wheelan join seven existing board members representing ... Barry Freedman is President and Chief Executive Officer ...
... GSI Group Inc.,(Nasdaq: GSIG ), a leading ... it will be presenting at both the,Needham & Company ... January,10th and the Fifth Annual Sidoti & Company Emerging ... Mr. Robert Bowen, Chief Financial Officer, will be speaking ...
... Jan. 9 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX -,News) stated ... of,AlphaRx Inc Common Stock in the open market, bringing ... last 60 days, reflecting his,continued confidence in the Company,s ... of 720,000 AlphaRx shares for,an average price of $0.24 ...
... 2008 Meeting of the American Psychoanalytic Association, psychoanalysts Susan ... Ph.D. (Boston, MA) will lead a discussion regarding "Psychoanalytic ... Dialogue between Psychoanalysis and Neurobiology." This session will be ... 10: 00 pm at the Waldorf-Astoria Hotel, 301 Park ...
Cached Medicine News:Health News:Judge Rules Texas Mutual Insurance Co. Committed Litigation Fraud With Falsified Document, According to Doyle Raizner LLP 2Health News:Kim & Scott's Gourmet Pretzels(R) Introduces Its First Empowered Pretzel(TM) Available Online and to Wholesale 2Health News:MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors 2Health News:MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors 3Health News:GSI to Present at Upcoming Investor Growth Conferences 2
... revised charts incorporate the slight change in ... 10 Sloan letters derived from the best ... during the ETDRS study. The original charts ... of 234 eyes. In addition to the ...
... The Stereo Tower is used to ... and adults without the use of ... tests can be used for study, testing ... form and depth perception. The instruction card ...
... to simplify stereopsis screening in children. It is ... gratings. Lang Stereotest II measures disparities: Moon and ... seconds of arc plus monocularly visible star. In ... are smaller and less dense. This disparity is ...
... This "natural" Stereotest consists of three test plates(6mm, ... measurements in a range of 600 - 15 ... shape can only be detected if stereopsis is ... the risk of the patient learning the correct ...
Medicine Products: